Episodes 1-15 of 845
Highlights of the Latest Hypertension Guidelines
CardiologyHighlights of the Latest Hypertension Guidelines
Clinical Perspective on New Therapies in Resistant Hypertension
CardiologyClinical Perspective on New Therapies in Resistant Hypertension
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart MattersTargeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CMExploring Patient Perspectives on Genetic Testing for ATTR-CM
- advertisement
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
CardiologyPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
CardiologyDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
CardiologyDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiologyPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
- advertisement
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
CardiologyADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
CardiologyOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
CardiologyPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
